247 related articles for article (PubMed ID: 27379402)
21. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
Zhou X; Mould DR; Takubo T; Sheldon-Waniga E; Huebner D; Milton A; Venkatakrishnan K
Br J Clin Pharmacol; 2018 Jan; 84(1):35-51. PubMed ID: 28891222
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S
J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
25. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
[TBL] [Abstract][Full Text] [Related]
26. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
Liu G; Wang C; He Y; E M
BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
28. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.
Yu H; van Erp N; Bins S; Mathijssen RH; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Clin Pharmacokinet; 2017 Mar; 56(3):293-303. PubMed ID: 27534647
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.
Zhou X; Ouerdani A; Diderichsen PM; Gupta N
J Clin Pharmacol; 2022 Mar; 62(3):422-433. PubMed ID: 34564871
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Li J; Al-Huniti N; Henningsson A; Tang W; Masson E
Br J Clin Pharmacol; 2017 Aug; 83(8):1723-1733. PubMed ID: 28213941
[TBL] [Abstract][Full Text] [Related]
32. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
33. Apatinib for the treatment of gastric cancer.
Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ding J; Chen X; Dai X; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():108-15. PubMed ID: 22503745
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
Dallinger C; Trommeshauser D; Marzin K; Liesener A; Kaiser R; Stopfer P
J Clin Pharmacol; 2016 Nov; 56(11):1387-1394. PubMed ID: 27093880
[TBL] [Abstract][Full Text] [Related]
38. Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.
Zhu YT; Teng Z; Zhang YF; Li W; Guo LX; Liu YP; Qu XJ; Wang QR; Mao SY; Chen XY; Zhong DF
Drug Des Devel Ther; 2020; 14():1963-1970. PubMed ID: 32546963
[TBL] [Abstract][Full Text] [Related]
39. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
40. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
